Literature DB >> 22908168

Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses.

Giulia Muratore1, Beatrice Mercorelli, Laura Goracci, Gabriele Cruciani, Paul Digard, Giorgio Palù, Arianna Loregian.   

Abstract

AL18, an inhibitor of human cytomegalovirus DNA polymerase, was serendipitously found to also block the interaction between the PB1 and PA polymerase subunits of influenza A virus. Furthermore, AL18 effectively inhibited influenza A virus polymerase activity and the overall replication of influenza A and B viruses. A molecular model to explain the binding of AL18 to both cytomegalovirus and influenza targets is proposed. Thus, AL18 represents an interesting lead for the development of new antivirals.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22908168      PMCID： PMC3486565          DOI： 10.1128/AAC.01219-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  The crystal structure of an unusual processivity factor, herpes simplex virus UL42, bound to the C terminus of its cognate polymerase.

Authors:  H J Zuccola; D J Filman; D M Coen; J M Hogle
Journal:  Mol Cell       Date:  2000-02       Impact factor: 17.970

2.  Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit.

Authors:  Arianna Loregian; Brent A Appleton; James M Hogle; Donald M Coen
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit. Differences in structure and function relative to unliganded UL44.

Authors:  Brent A Appleton; Justin Brooks; Arianna Loregian; David J Filman; Donald M Coen; James M Hogle
Journal:  J Biol Chem       Date:  2005-12-20       Impact factor: 5.157

4.  A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application.

Authors:  Massimo Baroni; Gabriele Cruciani; Simone Sciabola; Francesca Perruccio; Jonathan S Mason
Journal:  J Chem Inf Model       Date:  2007 Mar-Apr       Impact factor: 4.956

5.  The crystal structure of PF-8, the DNA polymerase accessory subunit from Kaposi's sarcoma-associated herpesvirus.

Authors:  Jennifer L Baltz; David J Filman; Mihai Ciustea; Janice Elaine Y Silverman; Catherine L Lautenschlager; Donald M Coen; Robert P Ricciardi; James M Hogle
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

6.  Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.

Authors:  D F Smee; J H Huffman; A C Morrison; D L Barnard; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.

Authors:  Hans-Heinrich Hoffmann; Andrea Kunz; Viviana A Simon; Peter Palese; Megan L Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

8.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

9.  Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus.

Authors:  Xiaojing He; Jie Zhou; Mark Bartlam; Rongguang Zhang; Jianyuan Ma; Zhiyong Lou; Xuemei Li; Jingjing Li; Andrzej Joachimiak; Zonghao Zeng; Ruowen Ge; Zihe Rao; Yingfang Liu
Journal:  Nature       Date:  2008-07-09       Impact factor: 49.962

Review 10.  Antiviral agents active against influenza A viruses.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694
View more
  9 in total

1.  AZT acts as an anti-influenza nucleotide triphosphate targeting the catalytic site of A/PR/8/34/H1N1 RNA dependent RNA polymerase.

Authors:  Nataraj Sekhar Pagadala
Journal:  J Comput Aided Mol Des       Date:  2019-02-09       Impact factor: 3.686

2.  Discovery of novel SARS-CoV-2 inhibitors targeting the main protease Mpro by virtual screenings and hit optimization.

Authors:  Beatrice Mercorelli; Jenny Desantis; Marta Celegato; Alessandro Bazzacco; Lydia Siragusa; Paolo Benedetti; Michela Eleuteri; Federico Croci; Gabriele Cruciani; Laura Goracci; Arianna Loregian
Journal:  Antiviral Res       Date:  2022-06-07       Impact factor: 10.103

Review 3.  Antiviral strategies against influenza virus: towards new therapeutic approaches.

Authors:  Arianna Loregian; Beatrice Mercorelli; Giulio Nannetti; Chiara Compagnin; Giorgio Palù
Journal:  Cell Mol Life Sci       Date:  2014-04-04       Impact factor: 9.261

Review 4.  The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.

Authors:  Annelies Stevaert; Lieve Naesens
Journal:  Med Res Rev       Date:  2016-08-29       Impact factor: 12.944

5.  Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases.

Authors:  Matteo Santucci; Francesca Spyrakis; Simon Cross; Antonio Quotadamo; Davide Farina; Donatella Tondi; Filomena De Luca; Jean-Denis Docquier; Ana Isabel Prieto; Claudia Ibacache; Jesús Blázquez; Alberto Venturelli; Gabriele Cruciani; Maria Paola Costi
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

6.  Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.

Authors:  Serena Massari; Chiara Bertagnin; Maria Chiara Pismataro; Anna Donnadio; Giulio Nannetti; Tommaso Felicetti; Stefano Di Bona; Maria Giulia Nizi; Leonardo Tensi; Giuseppe Manfroni; Maria Isabel Loza; Stefano Sabatini; Violetta Cecchetti; Jose Brea; Laura Goracci; Arianna Loregian; Oriana Tabarrini
Journal:  Eur J Med Chem       Date:  2020-10-16       Impact factor: 6.514

Review 7.  Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins.

Authors:  Lingxin Hou; Ying Zhang; Han Ju; Srinivasulu Cherukupalli; Ruifang Jia; Jian Zhang; Bing Huang; Arianna Loregian; Xinyong Liu; Peng Zhan
Journal:  Acta Pharm Sin B       Date:  2021-11-19       Impact factor: 14.903

8.  Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant.

Authors:  Ruifang Jia; Jiwei Zhang; Jian Zhang; Chiara Bertagnin; Anna Bonomini; Laura Guizzo; Zhen Gao; Xiangkai Ji; Zhuo Li; Chuanfeng Liu; Han Ju; Xiuli Ma; Arianna Loregian; Bing Huang; Peng Zhan; Xinyong Liu
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

Review 9.  New small-molecule drug design strategies for fighting resistant influenza A.

Authors:  Zuyuan Shen; Kaiyan Lou; Wei Wang
Journal:  Acta Pharm Sin B       Date:  2015-09-06       Impact factor: 11.413
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.